公开(公告)号：WO2019161211A2

公开(公告)日：2019-08-22

申请号：PCT/US2019/018230

申请日：2019-02-15

Applicant: NUSIRT SCIENCES, INC.

Inventor： ZEMEL, Michael ,  BRUCKBAUER, Antje ,  BANERJEE, Jheelam

IPC: A61K31/575

Abstract: Methods useful for reducing or preventing hepatic steatosis and NASH are provided herein. Such methods may comprise administering to a subject in need thereof an FXR agonist in combination with an amount of a branched amino acid in free amino acid form, such as leucine, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.

公开(公告)号：WO2019161211A3

公开(公告)日：2019-08-22

申请号：PCT/US2019/018230

申请日：2019-02-15

Applicant: NUSIRT SCIENCES, INC.

Inventor： ZEMEL, Michael ,  BRUCKBAUER, Antje ,  BANERJEE, Jheelam

IPC: A61K31/13 ,  A61K47/06 ,  A61K47/28 ,  C07J5/00 ,  C07J9/00 ,  C07J51/00

Abstract: Methods useful for reducing or preventing hepatic steatosis and NASH are provided herein. Such methods may comprise administering to a subject in need thereof an FXR agonist in combination with an amount of a branched amino acid in free amino acid form, such as leucine, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.

公开(公告)号：WO2018045335A1

公开(公告)日：2018-03-08

申请号：PCT/US2017/049946

申请日：2017-09-01

Applicant: NUSIRT SCIENCES, INC.

Inventor： ZEMEL, Michael ,  BRUCKBAUER, Antje ,  BANERJEE, Jheelam

IPC: A61K31/22 ,  A61K31/23

CPC classification number: A61K31/495 ,  A61K31/04 ,  A61K31/155 ,  A61K31/196 ,  A61K31/198 ,  A61K31/401 ,  A61K31/4439 ,  A61K31/455 ,  A61K2300/00

Abstract: Methods useful for reducing or preventing non-alcoholic steatohepatitis or hepatic steatosis are provided herein. Such methods may comprise administering to a subject in need thereof a nitric oxide (NO) donor, a branched amino acid in free amino acid form, or a metabolite thereof, a sirtuin pathway activator, a PDE5 inhibitor alone or any combination thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.

Abstract translation: 本文提供了用于减少或预防非酒精性脂肪性肝炎或肝脂肪变性的方法。 此类方法可包括向需要其的受试者施用一氧化氮（NO）供体，游离氨基酸形式的支链氨基酸或其代谢物，单独的sirtuin通路活化剂，PDE5抑制剂或其任何组合。 本文还提供用于实施本文所述任何方法的组合物和试剂盒。